The Latest Breaking News from Bharat Biotech

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

A total of 374 adverse events were reported and majority of them were mild in nature and resolved within a day, said the company

The Hindu · Jun 17, 2022

COVID-19 | Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

New Delhi The administration of Covaxin as a booster dose enhances vaccine effectiveness against COV

The Hindu · Jun 15, 2022

US Food and Drug Administration lifts clinical hold, Covaxin trials to resume

HYDERABAD: The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine, Covaxin, in the US.

The Times of India · May 23, 2022

Drugs Controller allows restricted emergency use of Covaxin for 6-12 years

DCGI (Drugs Controller General of India) gives restricted emergency use authorisation to BharatBiotech's Covaxin for children between the age of 6-12 years. More details on Dynamite News:

Dynamite News · Apr 26, 2022

Paving the way for a global malaria vaccine

Malaria impacts India more than anywhere else in southeast Asia, but relief could be on the way if the early promise of vaccines in development is fulfilled.

360info · Apr 20, 2022

Why Ocugen Shares Are Trading Higher Today

Ocugen Inc (NASDAQ:OCGN) and Bharat Biotech have amended their co-development, supply, and commercialization agreement to expand Ocugen's exclusive territory to include the commercialization of Covaxin in Mexico.  This gives Ocugen Covaxin commercialization rights for all of North America. Covaxin can be an ideal vaccination option for Mexico at this pandemic stage. As a whole…

Benzinga · Apr 18, 2022

Morning Digest | Four militants behind J&K targeted killings shot dead; Covaxin trials in U.S. put on hold, and more

A select list of stories to read before you start your day

The Hindu · Apr 15, 2022

Covaxin’s Phase 2/3 clinical trials put on hold in the US

HYDERABAD: The US Food and Drug Administration has put on hold the phase 2/3 clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin in the US.

The Times of India · Apr 14, 2022

Covaxin trials in U.S. put on hold

WHO had announced suspension of the vaccine supplies through UN procurement agencies

The Hindu · Apr 14, 2022

FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial

The 

Benzinga · Apr 12, 2022